Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and ...

Designation Supported by CLOVER WaM Phase 2 Study DataWhich Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance ...

Cellectar's Iopofosine I 131 earned FDA breakthrough therapy designation for relapsed Waldenstrom macroglobulinemia following ...

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States.

Cellectar Biosciences, Inc. has announced that it will release its financial results for the first quarter ending March 31, 2025, along with a corporate update on May 13, 2025, at 8:30 a.m ...

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2024 Earnings Call Transcript March 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.38.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2024 Earnings Call Transcript August 13, 2024 Operator: Good morning, and welcome to Cellectar Biosciences Second Quarter 2024 Financial Results Call.

With yields above 6%, these stocks offer at least four times the payout of the typical blue-chip stock.

Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.17. Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time all ...

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...